JP2024032686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024032686A5 JP2024032686A5 JP2023137929A JP2023137929A JP2024032686A5 JP 2024032686 A5 JP2024032686 A5 JP 2024032686A5 JP 2023137929 A JP2023137929 A JP 2023137929A JP 2023137929 A JP2023137929 A JP 2023137929A JP 2024032686 A5 JP2024032686 A5 JP 2024032686A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharma
- acceptable salt
- compound according
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 23
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 208000024827 Alzheimer disease Diseases 0.000 claims 8
- 208000023105 Huntington disease Diseases 0.000 claims 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 8
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 8
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 8
- 208000018737 Parkinson disease Diseases 0.000 claims 8
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000006417 multiple sclerosis Diseases 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 208000025487 periodic fever syndrome Diseases 0.000 claims 8
- 230000009529 traumatic brain injury Effects 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 208000035690 Familial cold urticaria Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000031225 myocardial ischemia Diseases 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 230000003449 preventive effect Effects 0.000 claims 4
- 201000003274 CINCA syndrome Diseases 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108091008099 NLRP3 inflammasome Proteins 0.000 claims 2
- 229940127107 NLRP3 inflammasome inhibitor Drugs 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- -1 2,4-dimethoxybenzyl Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001925 cycloalkenes Chemical class 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000262 haloalkenyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024194113A JP2025013515A (ja) | 2022-08-29 | 2024-11-06 | ピラゾロピリミジン化合物及びその医薬用途 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022135949 | 2022-08-29 | ||
| JP2022135949 | 2022-08-29 | ||
| JP2023027426 | 2023-02-24 | ||
| JP2023027426 | 2023-02-24 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024194113A Division JP2025013515A (ja) | 2022-08-29 | 2024-11-06 | ピラゾロピリミジン化合物及びその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024032686A JP2024032686A (ja) | 2024-03-12 |
| JP2024032686A5 true JP2024032686A5 (enExample) | 2024-05-27 |
| JP7585409B2 JP7585409B2 (ja) | 2024-11-18 |
Family
ID=90099947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023137929A Active JP7585409B2 (ja) | 2022-08-29 | 2023-08-28 | ピラゾロピリミジン化合物及びその医薬用途 |
| JP2024194113A Pending JP2025013515A (ja) | 2022-08-29 | 2024-11-06 | ピラゾロピリミジン化合物及びその医薬用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024194113A Pending JP2025013515A (ja) | 2022-08-29 | 2024-11-06 | ピラゾロピリミジン化合物及びその医薬用途 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250114361A1 (enExample) |
| EP (1) | EP4582428A1 (enExample) |
| JP (2) | JP7585409B2 (enExample) |
| KR (1) | KR20250056233A (enExample) |
| CN (1) | CN119790055A (enExample) |
| AR (1) | AR130318A1 (enExample) |
| AU (1) | AU2023334673A1 (enExample) |
| CL (1) | CL2025000495A1 (enExample) |
| CO (1) | CO2025002359A2 (enExample) |
| IL (1) | IL319000A (enExample) |
| MX (1) | MX2025002450A (enExample) |
| PE (1) | PE20251551A1 (enExample) |
| TW (1) | TW202416965A (enExample) |
| WO (1) | WO2024048519A1 (enExample) |
| ZA (1) | ZA202501724B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024177126A1 (ja) * | 2023-02-24 | 2024-08-29 | 日本たばこ産業株式会社 | ６－アルコキシピラゾロピリミジン化合物及びその医薬用途 |
| KR20250151389A (ko) * | 2023-02-24 | 2025-10-21 | 니뽄 다바코 산교 가부시키가이샤 | 치환 피라졸로피리미딘 화합물 및 그의 의약 용도 |
| KR20250170647A (ko) | 2023-04-14 | 2025-12-05 | 다케다 야쿠힌 고교 가부시키가이샤 | Nlrp3 억제제로서의 피라졸로피리미딘 유도체 |
| CN120230110A (zh) * | 2023-12-31 | 2025-07-01 | 杭州百新生物医药科技有限公司 | 吡唑并嘧啶类化合物及其医药用途 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4146348T (pt) * | 2020-05-08 | 2024-10-04 | Halia Therapeutics Inc | Inibidores da quinase nek7 |
| CN116194445A (zh) * | 2020-09-24 | 2023-05-30 | 詹森药业有限公司 | 新化合物 |
| CN113549080B (zh) * | 2021-08-27 | 2023-05-16 | 中国医学科学院放射医学研究所 | 一类1,2,3-三氮唑并嘧啶类化合物、其制备方法和用途 |
| AR126912A1 (es) * | 2021-08-31 | 2023-11-29 | Japan Tobacco Inc | Compuestos de 6-aminopirazolopirimidina y su uso médico |
-
2023
- 2023-08-28 TW TW112132370A patent/TW202416965A/zh unknown
- 2023-08-28 KR KR1020257009740A patent/KR20250056233A/ko active Pending
- 2023-08-28 WO PCT/JP2023/030980 patent/WO2024048519A1/ja not_active Ceased
- 2023-08-28 US US18/705,065 patent/US20250114361A1/en active Pending
- 2023-08-28 EP EP23860281.7A patent/EP4582428A1/en active Pending
- 2023-08-28 JP JP2023137929A patent/JP7585409B2/ja active Active
- 2023-08-28 CN CN202380062735.4A patent/CN119790055A/zh active Pending
- 2023-08-28 AU AU2023334673A patent/AU2023334673A1/en active Pending
- 2023-08-28 IL IL319000A patent/IL319000A/en unknown
- 2023-08-28 AR ARP230102274A patent/AR130318A1/es unknown
- 2023-08-28 PE PE2025000467A patent/PE20251551A1/es unknown
-
2024
- 2024-11-06 JP JP2024194113A patent/JP2025013515A/ja active Pending
-
2025
- 2025-02-21 CL CL2025000495A patent/CL2025000495A1/es unknown
- 2025-02-25 ZA ZA2025/01724A patent/ZA202501724B/en unknown
- 2025-02-27 CO CONC2025/0002359A patent/CO2025002359A2/es unknown
- 2025-02-27 MX MX2025002450A patent/MX2025002450A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024032686A5 (enExample) | ||
| JP2023036007A5 (enExample) | ||
| EP2968287B1 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP6843930B2 (ja) | ニトロカテコールの投与計画 | |
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| JP2015511638A5 (enExample) | ||
| JP2016516020A5 (enExample) | ||
| JP2013536193A5 (enExample) | ||
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| JP2024120882A5 (enExample) | ||
| JP2013510883A5 (enExample) | ||
| RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
| JP2020514318A5 (enExample) | ||
| JP2009544618A5 (enExample) | ||
| JP2012521994A5 (enExample) | ||
| JPWO2024177126A5 (enExample) | ||
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2012522759A5 (enExample) | ||
| JP2008517923A5 (enExample) | ||
| JP2016510784A5 (enExample) | ||
| RU2018131440A (ru) | Антагонисты FimH, являющиеся производными маннозы, пригодные для лечения заболевания | |
| JP2019509315A5 (enExample) | ||
| JP2018537513A5 (enExample) | ||
| JP2009513713A5 (enExample) | ||
| KR20170031779A (ko) | 염증성 장애 또는 과증식성 장애의 치료를 위한 cPLA2 억제제로서의 활성을 갖는 2-옥소티아졸 화합물 |